問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
周獻堂
下載
2019-12-01 - 2025-12-31
Condition/Disease
Test Drug
Participate Sites2Sites
Recruiting2Sites
2023-10-17 - 2028-12-31
Participate Sites1Sites
Recruiting1Sites
2018-03-18 - 2024-10-31
2020-03-22 - 2023-09-29
Relapsed or Refractory Osteosarcoma
Lenvima Capsules 1mg, 4mg, 10mg; Etoposide 100 mg HEXAL, 20 mg/mL; Ifosfamide for injection
2020-08-01 - 2023-11-23
Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
ENTRECTINIB (RXDX-101)
2018-03-01 - 2020-12-29
Advanced Stage Newly Diagnosed Hodgkin Lymphoma
ADCETRIS
Terminated1Sites
全部
